• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

    2/3/25 6:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

    Fourth quarter 2024 webcast & conference call details

    Date: 

     

    Wednesday, February 19, 2025

    Time: 

     

    5 p.m. ET

    Webcast: 

     

    The live webcast can be accessed at www.exactsciences.com

    Telephone: 

     

    Domestic callers, dial 888-330-2384 

     

     

    International callers, dial +1 240-789-2701

               

     

    Access code for both domestic and international callers: 4437608

     A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

    About Exact Sciences Corp.

    A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250203349082/en/

    Erik Holznecht

    Exact Sciences Corp.

    [email protected]

    608-800-6605

    Get the next $EXAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    1/2/2024$91.00Hold → Buy
    The Benchmark Company
    12/14/2023$90.00Buy
    Guggenheim
    More analyst ratings